Elinzanetant Cuts Hot Flashes 73% via Dual NK1/NK3 Receptor Blockade

The Phase 3 trial published in JAMA Internal Medicine on September 16, 2025, is reshaping the menopause prescribing landscape into spring 2026. Bayer’s elinzanetant is the first dual neurokinin-1 and neurokinin-3 receptor antagonist to complete Phase 3 testing. The headline reduces to one line: 73% reduction in hot flash frequency and severity at week 12.

600+ women, 52 weeks, 120 mg daily

The trial enrolled over 600 postmenopausal women aged 40-65 across 83 sites in North America and Europe. Participants received 120 mg daily for 52 weeks. Effect emerged from week 8, hit 73% reduction at week 12, and held through week 52.

Effect size separates this drug from prior non-hormonal options. A separate JAMA Internal Medicine paper in the same window reported elinzanetant produced 74% reduction at week 12 versus 47% on placebo. The 27 percentage point gap is clinically meaningful by any standard.

Sleep scores improved alongside

A notable secondary finding: while the primary endpoint was hot flash, sleep scores moved together. Mean PROMIS Sleep Disturbance Short Form reductions at week 12 were -9.4 for elinzanetant and -5.7 for placebo. The -3.7 point difference is interpreted as meaningful in menopause sleep literature.

That said, investigators emphasized “comprehensive secondary benefit assessment was not within scope,” signaling that secondary endpoints should be read with caution.

The NK1/NK3 dual mechanism

Earlier non-hormonal options (SSRIs, gabapentin) modulate neurotransmitters broadly. Elinzanetant targets the hypothalamic KNDy neuron circuit directly. Estrogen decline in menopause drives this circuit into hyperactivity, producing hot flashes. NK3 blockade calms the hyperactivity. Adding NK1 blockade stabilizes the sleep-wake circuit alongside.

The implication is clear. Menopause hot flash is no longer an “estrogen replacement only” target. A hormone-independent pathway produces 73% reduction.

Side effect profile

The most common adverse effects were sleepiness, fatigue, and headache. No harmful effects on liver function or bone density were detected. Critically, the mechanism does not produce endometrial or breast tissue stimulation, the classic concerns with HRT.

The FDA delayed its approval decision in July 2025, requesting additional review time from Bayer. As of spring 2026, EMA and MHRA approval processes are in motion, with US market entry timing pending further data review.

Reshaping the prescribing landscape

Two industry messages emerge. First, non-hormonal options have moved from SSRI adjuncts to mechanism-based targeted drugs. Second, a Phase 3 effect size of 73% brings non-hormonal therapy near clinical parity with HRT for hot flash control for the first time.

For women, the impact is direct. Patients for whom HRT is unsuitable (history of breast cancer, thrombotic risk, or personal preference) now have a non-hormonal option with clinically meaningful effect size. Menopause symptom management moves from “HRT-eligible vs not” to a mechanism-by-mechanism options matrix. This trial is the inflection point.